Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer Research Summary

Дата публикации: 23-10-2026 00:00:00

This trial compared trastuzumab rezetecan vs physician’s choice of chemotherapy in patients with erythroblastic oncogene B (ERBB2)–low metastatic breast cancer.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer	0	15.98	23-10-2026
2	Trastuzumab Rezetecan in EBBR2-Low Metastatic Breast Cancer	0	9.5	23-10-2026
3	‘Why do I have this cancer?’ At CNIO, breast cancer research gets personal	0	10.34	21-10-2026
4	SGLT2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron, and Erythropoiesis	0	15.52	24-10-2026
5	The Rise in Testosterone Therapy for Women	0	7.16	23-10-2026
6	New therapeutic strategy could open the door to preventing brain metastasis	0	7.7	29-09-2026
7	More than 30K walk Tampa for breast cancer awareness	0	7.2	24-10-2026
8	El olfato de los perros al servicio de la detección temprana del cáncer de mama: “Las mujeres que donan la muestra lo hacen con la esperanza de que otras tengan el camino más fácil”	0	5.13	19-10-2026
9	Rays face Brewers in Game 2 of World Series after Friday loss	0	8.41	24-10-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 12.56. Источник: www.jamanetwork.com.